NOV to Report Q2 Earnings: What's in Store for the Stock?
NOV faces a key Q2 test as delayed shipments, strong order trends and cost cuts collide with ongoing logistics and drilling headwinds.
NOV - NOV Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$20.88
DETAILS
HIGH:
$26.00
LOW:
$18.00
MEDIAN:
$21.00
CONSENSUS:
$20.88
UPSIDE:
0.58%
Stock News
Nov Inc. (NOV) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Nov Inc. (NOV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NOV Stock Rallies 49% in a Year: Time to Buy or Move On?
NOV's technology gains, rising earnings estimates, strong backlog and shareholder returns strengthen its long-term outlook despite trailing some peers.
NOV vs. SLB N.V.: Which Energy Stock Is a Better Buy in 2026?
NOV provides a conservative balance sheet with a current ratio of roughly 2.4x and low debt levels. SLB N.V. leverages a massive global footprint to generate substantial free cash flow nearing $4.8 billion.
Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn's Disease
-- Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design, including novel primary endpoint of endoscopic passability -- -- Study initiation on track, with first participants expected to be dosed in the second half of 2026 -- Antwerp, Belgium, June 23, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (or TGF-β RI) for the potential treatment of Fibrostenosing Crohn's Disease (FSCD). Approximately 46% of Crohn's disease patients have FSCD, or fibrotic strictures in the intestinal tract, which can cause obstructive symptoms leading to dietary change, malnutrition and surgery.
NOV Announces Second Quarter 2026 Earnings Conference Call
HOUSTON, June 16, 2026 (GLOBE NEWSWIRE) -- NOV Inc. (NYSE: NOV) will hold a conference call to discuss its second quarter 2026 results on Wednesday, July 29, 2026, at 10 a.m. (Central Time).
NOV Stock Gains 32% in Six Months: Should Investors Hold or Move On?
NOV shares rise 32% over the past six months as offshore demand, backlog growth and efficiency gains boost prospects despite tariffs and risks.
Why Is Nov Inc. (NOV) Up 4.1% Since Last Earnings Report?
Nov Inc. (NOV) reported earnings 30 days ago. What's next for the stock?
NOV Declares Regular Quarterly Dividend and Supplemental Dividend
HOUSTON, May 21, 2026 (GLOBE NEWSWIRE) -- NOV Inc. (NYSE: NOV) announced today that its Board of Directors declared a regular quarterly cash dividend of $0.09 per share of common stock, payable on June 26, 2026 to each stockholder of record on June 12, 2026.
Solaris Energy Q1 Earnings Crush Estimates on Power Growth
SEI's Q1 profit jumped 120%, and revenues rose 55% as Power Solutions scaled, aided by behind-the-meter data center power demand.
NOV Q1 Earnings Miss Estimates, Revenues Beat, Decrease Y/Y
NOV Q1 earnings miss estimates as Middle East disruptions hit operations, while revenues edge past expectations despite a year-over-year decline.
While Asia and Europe scramble for natural gas, the US glut has nowhere to go
The war with Iran has boosted prices of globally traded natural gas by throttling exports from the Gulf. In West Texas, gas is so abundant that some producers must pay to have it taken away.
NOV Inc. (NOV) Q1 2026 Earnings Call Transcript
NOV Inc. (NOV) Q1 2026 Earnings Call Transcript
Compared to Estimates, Nov Inc. (NOV) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Nov Inc. (NOV) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Nov Inc. (NOV) Lags Q1 Earnings Estimates
Nov Inc. (NOV) came out with quarterly earnings of $0.15 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.19 per share a year ago.
NOV Reports First Quarter 2026 Earnings
*Free Cash Flow, Excess Free Cash Flow, Adjusted Operating Profit, and Adjusted EBITDA are non-GAAP measures, see “Non-GAAP Financial Measures,” and “Reconciliation of GAAP to non-GAAP measures” below.
NOV Reports First Quarter 2026 Earnings
Revenues of $2. 05 billion Net income of $19 million, or $0. 05 per share Adjusted EBITDA* of $177 million Bookings of $520 million, representing a book-to-bill of 80% Returned $100 million of capital to shareholders through share repurchases and dividends *Free Cash Flow, Excess Free Cash Flow, Adjusted Operating Profit, and Adjusted EBITDA are non-GAAP measures, see "Non-GAAP Financial Measures," and "Reconciliation of GAAP to non-GAAP measures" below.
NOV to Report Q1 Earnings: What's in Store for the Stock?
NOV faces Q1 pressure as disruptions, weak drilling demand and cost inflation weigh despite offshore strength and backlog offering potential upside.
Earnings Preview: Nov Inc. (NOV) Q1 Earnings Expected to Decline
Nov Inc. (NOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NOV Q1 2026 Outlook Hit by Middle East Conflict Disruptions
NOV expects weaker Q1 results as Middle East conflict delays deliveries, raises costs and pressures margins despite stable global operations.
Price Targets
NOV Inc. price target raised to $21 from $20 at Morgan Stanley
$21.00
(was $19.36)
Morgan Stanley
NOV Inc. price target lowered to $22 from $24 at Susquehanna
$22.00
(was $18.28)
Susquehanna
NOV Inc. upgraded to Overweight from Equalweight at Capital One
$26.00
(was $21.18)
Capital One Financial
NOV Inc. price target lowered to $19 from $20 at Goldman Sachs
$19.00
(was $20.82)
Goldman Sachs
NOV Inc. downgraded to Underweight from Equal Weight at Barclays
$21.00
(was $20.18)
David Anderson
·
Barclays
NOV Inc. price target raised to $24 from $22 at Susquehanna
$24.00
(was $20.29)
Susquehanna
NOV Inc. price target raised to $20 from $18 at Morgan Stanley
$20.00
(was $19.10)
Morgan Stanley
NOV Inc. price target raised to $18 from $17 at Piper Sandler
$18.00
(was $18.91)
Derek Podhaizer
·
Piper Sandler
NOV Inc. price target raised to $19 from $15 at Evercore ISI
$19.00
(was $18.75)
Jason Bandel
·
Evercore ISI
NOV Inc. price target raised to $21 from $19 at Stifel
$21.00
(was $18.78)
Stifel Nicolaus
NOV Inc. price target raised to $21 from $20 at Susquehanna
$21.00
(was $18.24)
Susquehanna
NOV Inc. price target raised to $21 from $19 at RBC Capital
$21.00
(was $17.93)
Keith Mackey
·
RBC Capital
NOV Inc. price target raised to $17 from $14 at Goldman Sachs
$17.00
(was $17.72)
Goldman Sachs
NOV Inc. price target raised to $20 from $17 at Susquehanna
$20.00
(was $17.06)
Charles Minervino
·
Susquehanna
NOV Inc. price target raised to $17 from $14 at Piper Sandler
$17.00
(was $15.66)
Derek Podhaizer
·
Piper Sandler
NOV Inc. price target raised to $15 from $13 at Barclays
$15.00
(was $15.32)
Barclays
NOV Inc. downgraded to Equal Weight from Overweight at Morgan Stanley
$16.00
(was $16.09)
Joe Laetsch
·
Morgan Stanley
NOV Inc. price target lowered to $13 from $14 at Barclays
$13.00
(was $15.64)
David Anderson
·
Barclays
NOV Inc. price target raised to $14 from $12 at Goldman Sachs
$14.00
(was $14.88)
Ati Modak
·
Goldman Sachs
NOV Inc. price target raised to $14 from $11 at Barclays
$14.00
(was $15.31)
Barclays